Search

Your search keyword '"Del Mastro L"' showing total 865 results
Start Over Author "Del Mastro L"
865 results on '"Del Mastro L"'

51. 113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials

Author

Ruelle, T., primary, Perachino, M., additional, Blondeaux, E., additional, Bruzzone, M., additional, Fozza, A., additional, Garlaschi, A., additional, Belgioia, L., additional, Pitto, F., additional, Levaggi, A., additional, Sparavigna, M., additional, Del Mastro, L., additional, Lambertini, M., additional, and Fregatti, P., additional

Published
2022
Full Text
View/download PDF

52. 177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)

Author

Gampenrieder, S.P., primary, Dezentjé, V., additional, Lambertini, M., additional, de Nonneville, A., additional, Marhold, M., additional, Le Du, F., additional, Saavedra Serrano, C., additional, Alpuim Costa, D., additional, Blondeaux, E., additional, Del Mastro, L., additional, Bertucci, F., additional, Gonçalves, A., additional, Bartsch, R., additional, Deleuze, A., additional, Cortés Salgado, A., additional, Vitorino, M., additional, Tinchon, C., additional, Pecen, L., additional, Rinnerthaler, G., additional, and Greil, R., additional

Published
2022
Full Text
View/download PDF

53. Putting the Taxanes to Work: Unanswered Questions

Author

Conte, P. F., Del Mastro, L., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Senn, Hans-Jörg, editor, Gelber, Richard D., editor, Goldhirsch, Aron, editor, and Thürlimann, Beat, editor

Published
1998
Full Text
View/download PDF

54. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer

Author

Pagliuca, M., Donato, M., D'Amato, A. L., Rosanova, M., Russo, A. O. M., Scafetta, R., De Angelis, C., Trivedi, M. V., André, F., Arpino, G., Del Mastro, L., De Laurentiis, M., Puglisi, F., and Giuliano, M.

Subjects
Selective Estrogen Receptor Modulators, SERDs, Breast Neoplasms, Estrogens, Hematology, ER signaling, Phosphatidylinositol 3-Kinases, SERCAs, PROTACs, Receptors, Estrogen, Oncology, Quality of Life, Humans, Female, Endocrine resistance
Abstract

Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in hormone receptor positive (HR+) breast cancer (BC). Thus, endocrine therapy (ET) alone or in combination with targeted agents constitutes the mainstay of the treatment for this BC subtype. Despite its efficacy, intrinsic or acquired resistance to ET occurs in a large proportion of cases, mainly due to aberrant activation of ER signaling (i.e. through ligand-independent ER activation, in the presence of estrogen receptor 1 (ESR1) gene aberration or ER protein phosphorylation) and/or the upregulation of escape pathways, such as the PI3K/AKT/mTOR pathway. Therefore, the development of new ER pathway targeting agents remains essential to delay and overcome ET resistance, enhance treatment efficacy and tolerability, and ultimately prolong patient survival and improve their quality of life. Several novel ER targeting agents are currently under investigation. Among these, the oral selective ER degraders (SERDs) represent the pharmacological class at the most advanced stage of development and promise to enrich the therapeutic armamentarium of HR+ BC in the next few years, as they showed promising results in several clinical trials, either as single ET agents or in combination with targeted therapies. In this manuscript, we aim to provide a comprehensive overview on the clinical development of novel ER targeting agents, reporting the most up-to-date evidence on oral SERDs and other compounds, including new selective ER modulators (SERMs), ER proteolysis targeting chimera (PROTACs), selective ER covalent antagonists (SERCAs), complete ER antagonists (CERANs), selective human ER partial agonists (ShERPAs). Furthermore, we discuss the potential implications of introducing these novel treatment strategies in the evolving and complex therapeutic scenario of HR+ BC.

Published
2022

57. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis

Author

Arecco, L, primary, Blondeaux, E, additional, Bruzzone, M, additional, Ceppi, M, additional, Latocca, M M, additional, Marrocco, C, additional, Boutros, A, additional, Spagnolo, F, additional, Razeti, M G, additional, Favero, D, additional, Spinaci, S, additional, Condorelli, M, additional, Massarotti, C, additional, Goldrat, O, additional, Del Mastro, L, additional, Demeestere, I, additional, and Lambertini, M, additional

Published
2022
Full Text
View/download PDF

59. C25 - Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

Author

Pronzato, P., Mustacchi, G., Riccardi, F., Turletti, A., Michelotti, A., Natoli, C., Livi, L., Del Mastro, L., Donadio, M., Garrone, O., Giordano, M., De Laurentiis, M., Marchetti, P., Montemurro, F., Romagnoli, E., De Placido, S., Biganzoli, L., and Cazzaniga, M.

Published
2017
Full Text
View/download PDF

63. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Author

Harbeck, N., primary, Rastogi, P., additional, Martin, M., additional, Tolaney, S.M., additional, Shao, Z.M., additional, Fasching, P.A., additional, Huang, C.S., additional, Jaliffe, G.G., additional, Tryakin, A., additional, Goetz, M.P., additional, Rugo, H.S., additional, Senkus, E., additional, Testa, L., additional, Andersson, M., additional, Tamura, K., additional, Del Mastro, L., additional, Steger, G.G., additional, Kreipe, H., additional, Hegg, R., additional, Sohn, J., additional, Guarneri, V., additional, Cortés, J., additional, Hamilton, E., additional, André, V., additional, Wei, R., additional, Barriga, S., additional, Sherwood, S., additional, Forrester, T., additional, Munoz, M., additional, Shahir, A., additional, San Antonio, B., additional, Nabinger, S.C., additional, Toi, M., additional, Johnston, S.R.D., additional, O’Shaughnessy, J., additional, Jimenez, M.M., additional, Johnston, S., additional, Boyle, F., additional, Neven, P., additional, Jiang, Z., additional, Campone, M., additional, Huober, J., additional, Shimizu, C., additional, Cicin, I., additional, Wardley, A., additional, Abuin, G.G., additional, Zarba, J., additional, Lim, E., additional, Sant, P., additional, Liao, N., additional, Christiansen, B., additional, Eigeliene, N., additional, Martin-Babau, J., additional, Ettl, J., additional, Mavroudis, D., additional, Chiu, J., additional, Boer, K., additional, Nagarkar, R., additional, Paluch-Shimon, S., additional, Moscetti, L., additional, Sagara, Y., additional, Kim, S.-B., additional, Maciel, M.M., additional, Tjan-Heijnen, V., additional, Broom, R., additional, Lacko, A., additional, Schenker, M., additional, Volkov, N., additional, Sim Yap, Y., additional, Coccia-Portugal, M., additional, Ángel García Sáenz, J., additional, Andersson, A., additional, Chao, T.-Y., additional, Gokmen, E., additional, Harputluoglu, H., additional, Berzoy, O., additional, Patt, D., additional, McArthur, H., additional, Chew, H., additional, Chalasani, P., additional, Kaufman, P., additional, Tedesco, K., additional, and Graff, S.L., additional

Published
2021
Full Text
View/download PDF

69. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

Author

Blondeaux, E., primary, Boni, L., additional, Ruelle, T., additional, Di Lauro, V., additional, Molinelli, C., additional, Piezzo, M., additional, Fratini, B., additional, Poggio, F., additional, Pugliese, P., additional, Ferzi, A., additional, Buzzatti, G., additional, Russo, S., additional, Garrone, O., additional, Gasparro, S., additional, D'Alonzo, A., additional, De Laurentiis, M., additional, Fabi, A., additional, Arpino, G., additional, Bighin, C., additional, and Del Mastro, L., additional

Published
2021
Full Text
View/download PDF

70. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

Author

Del Mastro, L., primary, Mansutti, M., additional, Bisagni, G., additional, Ponzone, R., additional, Durando, A., additional, Amaducci, L., additional, Cognetti, F., additional, Frassoldati, A., additional, Michelotti, A., additional, Mura, S., additional, Urracci, Y., additional, Sanna, G., additional, Gori, S., additional, De Placido, S., additional, Garrone, O., additional, Barone, C., additional, Bighin, C., additional, Poggio, F., additional, Lambertini, M., additional, and Bruzzi, P., additional

Published
2021
Full Text
View/download PDF

71. 131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer

Author

Franzoi, M.A., primary, Martel, S., additional, Agbor-Tarh, D., additional, Piccart, M., additional, Bines, J., additional, Loibl, S., additional, Di Cosimo, S., additional, Vaz-Luis, I., additional, Di Meglio, A., additional, Del Mastro, L., additional, Gombos, A., additional, Desmedt, C., additional, Jerusalem, G., additional, Reaby, L., additional, Pienkowski, T., additional, Lambertini, M., additional, and de Azambuja, E., additional

Published
2021
Full Text
View/download PDF

72. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes

Author

Cerbone, L., primary, Blondeaux, E., additional, Boni, L., additional, Ruelle, T., additional, Russo, S., additional, Bonotto, M., additional, Targato, G., additional, De Laurentiis, M., additional, Piezzo, M., additional, Arpino, G., additional, Pugliese, P., additional, Fabi, A., additional, D'Alonzo, A., additional, Giannubilo, I., additional, Conte, B., additional, Mulinelli, C., additional, Lambertini, M., additional, Bighin, C., additional, and Del Mastro, L., additional

Published
2021
Full Text
View/download PDF

73. 141P Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC)

Author

Dugo, M., primary, Gyorffy, B., additional, Bisagni, G., additional, Colleoni, M.A., additional, Mansutti, M., additional, Zamagni, C., additional, Del Mastro, L., additional, Zambelli, S., additional, Frassoldati, A., additional, Licata, L., additional, Galbardi, B., additional, Biasi, O.M., additional, Viganò, L., additional, Locatelli, A., additional, Viale, G., additional, Valagussa, P., additional, Callari, M., additional, Gianni, L., additional, and Bianchini, G., additional

Published
2021
Full Text
View/download PDF

74. 1694P Coffee and tea consumption (CTC), patient-reported (PRO), and clinical outcomes in a longitudinal study of patients (pts) with breast cancer (BC)

Author

Soldato, D., primary, Havas, J., additional, Presti, D., additional, Lapidari, P., additional, Rassy, N., additional, Pistilli, B., additional, Martin, E., additional, Del Mastro, L., additional, Martin, A-L., additional, Jacquet, A., additional, Coutant, C., additional, Cottu, P.H., additional, Merimèche, A., additional, Lerebours, F., additional, Tredan, O., additional, Vanlemmens, L., additional, André, F., additional, Vaz-Luis, I., additional, and Di Meglio, A., additional

Published
2021
Full Text
View/download PDF

75. 292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Author

Malorni, L., primary, De Laurentiis, M., additional, Bianchini, G., additional, Zambelli, A., additional, Puglisi, F., additional, Bianchi, G.V., additional, Del Mastro, L., additional, Paris, I., additional, Montemurro, F., additional, Allegrini, G., additional, Colleoni, M.A., additional, Tamberi, S., additional, Zamagni, C., additional, Cazzaniga, M.E., additional, Orditura, M., additional, Guarneri, V., additional, Castelletti, D., additional, Benelli, M., additional, Di Marino, M., additional, and Arpino, G., additional

Published
2021
Full Text
View/download PDF

76. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Author

De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., and Arpino, G.

Published
2021
Full Text
View/download PDF

77. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Author

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E., Conte P., Frassoldati A., Bisagni G., Brandes A.A., Donadio M., Garrone O., Piacentini F., Cavanna L., Giotta F., Aieta M., Gebbia V., Molino A., Musolino A., Ferro A., Maltoni R., Danese S., Zamagni C., Rimanti A., Cagossi K., Russo A., Pronzato P., Giovanardi F., Moretti G., Lombardo L., Schirone A., Beano A., Amaducci L., Bajardi E.A., Vicini R., Balduzzi S., D'Amico R., and Guarneri V.

Subjects
Oncology, Time Factors, Adjuvant, Breast cancer, Cardiac safety, De-escalated treatment, Trastuzumab, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, medicine.medical_treatment, Anthracycline, 030204 cardiovascular system & hematology, Breast cancer, Antineoplastic Agents, Immunological, ErbB-2, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Anthracyclines, skin and connective tissue diseases, Adjuvant, Mastectomy, Cardiac safety, De-escalated treatment, Hazard ratio, Hematology, Middle Aged, Chemotherapy regimen, Bridged-Ring Compound, Immunological, Local, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Taxoids, Trastuzumab, adjuvant, breast cancer, cardiac safety, de-escalated treatment, Breast Neoplasm, Human, Receptor, medicine.drug, Adult, Bridged-Ring Compounds, medicine.medical_specialty, Time Factor, Socio-culturale, Breast Neoplasms, Antineoplastic Agents, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Taxoid, Internal medicine, medicine, Humans, Chemotherapy, Risk factor, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocol, business.industry, medicine.disease, Cardiotoxicity, Neoplasm Recurrence, Neoplasm Recurrence, Local, business
Abstract

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)

Published
2018

79. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Miles, D., primary, Gligorov, J., additional, André, F., additional, Cameron, D., additional, Schneeweiss, A., additional, Barrios, C., additional, Xu, B., additional, Wardley, A., additional, Kaen, D., additional, Andrade, L., additional, Semiglazov, V., additional, Reinisch, M., additional, Patel, S., additional, Patre, M., additional, Morales, L., additional, Patel, S.L., additional, Kaul, M., additional, Barata, T., additional, O’Shaughnessy, J., additional, Zhang, Q., additional, Shao, Z., additional, Wang, X., additional, Geng, C., additional, Yan, X., additional, Tong, Z., additional, Shen, K., additional, Yin, Y., additional, Sun, T., additional, Yang, J., additional, Feng, J., additional, Yan, M., additional, Wang, Y., additional, Liu, Q., additional, Zhang, S., additional, De Laurentiis, M., additional, Santoro, A., additional, Guarneri, V., additional, Colleoni, M., additional, Natoli, C., additional, Cortesi, L., additional, Placido, S., additional, Gianni, L., additional, Ferrau, F., additional, Livi, L., additional, Zambelli, A., additional, Del Mastro, L., additional, Tonini, G., additional, Montemurro, F., additional, Bianchi, G., additional, Pedersini, R., additional, Prete, S., additional, Allegrini, G., additional, Naso, G., additional, Vici, P., additional, Loirat, D., additional, Mailliez, A., additional, Priou, F., additional, Tredan, O., additional, Dalenc, F., additional, Perrin, C., additional, Timar David, M., additional, Dohollou, N., additional, Teixeira, L., additional, Brocard, F., additional, Arnaud, A., additional, Delaloge, S., additional, Spano, J.-P., additional, Mansi, L., additional, Damian, F., additional, Pedrini, J., additional, Aleixo, S., additional, Hegg, R., additional, Junior, R., additional, Schmidt, M., additional, Wenzel, C., additional, Grischke, E.-M., additional, Just, M., additional, Harbeck, N., additional, Schumacher, C., additional, Peters, U., additional, Fischer, D., additional, Forstbauer, H., additional, Liersch, R., additional, Warner, E., additional, Bouganim, N., additional, Doyle, C., additional, Price Hiller, J., additional, Vandenberg, T., additional, Pavic, M., additional, Robinson, A., additional, Roldan Urgoiti, G., additional, Califaretti, N., additional, Alacacioglu, A., additional, Gumus, M., additional, Yalcin, B., additional, Cicin, I., additional, Kose, F., additional, Uygun, K., additional, Kaplan, M., additional, Cubukcu, E., additional, Harries, M., additional, Miles, D., additional, Doval, D., additional, Gupta, S., additional, Mohapatra, P., additional, Chatterjee, S., additional, Ghadyalpatil, N., additional, Singhal, M., additional, Nag, S., additional, Agarwal, A., additional, Wolf, I., additional, Gal Yam, E., additional, Yerushalmi, R., additional, Peretz, T., additional, Fried, G., additional, Ben Baruch, N., additional, Katz, D., additional, Hamilton, E., additional, Kayali, F., additional, Brufsky, A., additional, Telli, M., additional, Wright, G., additional, Oyola, R., additional, Rakowski, T., additional, Graff, S., additional, Tjulandin, S., additional, Aparicio, A., additional, Ruiz Borrego, M., additional, Merino, L., additional, Guerra Martinez, J., additional, Lopez, E., additional, Yamashita, T., additional, Ohtani, S., additional, Inoue, K., additional, Ito, Y., additional, Niikura, N., additional, Nakayama, T., additional, Sagara, Y., additional, Yanagita, Y., additional, Kamada, Y., additional, Kaneko, K., additional, Nervo, A., additional, Eniu, A., additional, Schenker, M., additional, Priester, P., additional, Melichar, B., additional, Zimovjanova, M., additional, Sormova, P., additional, Sufliarsky, J., additional, Kakalejcik, M., additional, Belbaraka, R., additional, Errihani, H., additional, Le Than, D., additional, Pham, D., additional, Aravantinos, G., additional, Papadimitriou, C., additional, Koumakis, G., additional, Papandreou, C., additional, Podolski, P., additional, and Tabane, K., additional

Published
2021
Full Text
View/download PDF

80. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer

Author

Reinisch, M, additional, O’Shaughnessy, J, additional, Rastogi, P, additional, Johnston, S, additional, Martin, M, additional, Harbeck, N, additional, Toi, M, additional, YH, Im, additional, Shao, ZM, additional, Kellokumpu Lehtinen, PL, additional, Huang, CS, additional, Tryakin, A, additional, Goetz, M, additional, Rugo, H, additional, Senkus, E, additional, Testa, L, additional, Andersson, M, additional, Tamura, K, additional, Steger, G, additional, Del Mastro, L, additional, Cox, J, additional, Forrester, T, additional, Sherwood, S, additional, Li, X, additional, and Wei, R, additional

Published
2021
Full Text
View/download PDF

81. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Author

Bergh, J, Pritchard, K, Swain, S, Cameron, D, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordstrom, E, Bliss, J, Bradley, R, Brain, E, Braybrooke, J, Carey, L, Clarke, M, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dodwell, D, Dowsett, M, Duane, F, Ejlertsen, B, Francis, P, Gelber, R, Gnant, M, Goetz, M, Goodwin, P, Gray, R, Halpin-Murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Liu, Z, Loibl, S, MacKinnon, E, Mamounas, E, Mannu, G, Martin, M, McGale, P, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pan, H, Peto, R, Piccart, M, Pierce, L, Poortmans, P, Raina, V, Rea, D, Regan, M, Robertson, J, Rutgers, E, Slamon, D, Spanic, T, Sparano, J, Steger, G, Taylor, C, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Bergh, J, Pritchard, K, Swain, S, Cameron, D, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordstrom, E, Bliss, J, Bradley, R, Brain, E, Braybrooke, J, Carey, L, Clarke, M, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dodwell, D, Dowsett, M, Duane, F, Ejlertsen, B, Francis, P, Gelber, R, Gnant, M, Goetz, M, Goodwin, P, Gray, R, Halpin-Murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Liu, Z, Loibl, S, MacKinnon, E, Mamounas, E, Mannu, G, Martin, M, McGale, P, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pan, H, Peto, R, Piccart, M, Pierce, L, Poortmans, P, Raina, V, Rea, D, Regan, M, Robertson, J, Rutgers, E, Slamon, D, Spanic, T, Sparano, J, Steger, G, Taylor, C, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, and Wolmark, N

Abstract

BACKGROUND: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. METHODS: We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs). FINDINGS: Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between February, 2000, and December, 2005. Mean scheduled treatment duration was 14·4 months and median follow-up was 10·7 years (IQR 9·5 to 11·9). The risks of breast cancer recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001) and death from breast cancer (0·67, 0·61 to 0·73; p<0·0001) were lower with trastuzumab plus chemotherapy than with chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9·0% (95% CI 7·4 to 10·7; p<0·0001) and 10-year breast cancer mortality was reduced by 6·4% (4·9 to 7·8; p<0·0001), with a 6·5% reduction (5·0 to 8·0; p<0·0001) in all-cause mortality, and no increase in death without recurrence (0·4%, -0·3 to 1·1; p=0·35). The proportional reduction in recurrence

Published
2021

83. LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

Author

Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton Torres, A., Bianchini, G., Sevillano Fernandez, E., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M.A., Kelly, C.M., Mariani, G., Del Mastro, L., Spezia, R., Ali, H., and Viale, G.

Published
2023
Full Text
View/download PDF

85. 352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial

Author

Vernieri, C., Ligorio, F., Dieci, M.V., Lambertini, M., De Angelis, C., Iorfida, M., Botticelli, A., Strina, C., Vingiani, A., Provenzano, L., Bianchi, G.V., Folli, S., Generali, D., Zambelli, A., de Placido, S., Del Mastro, L., Guarneri, V., Capri, G., Pruneri, G., and De Braud, F.G.M.

Published
2023
Full Text
View/download PDF

90. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author

De Placido, S, Gallo, C, De Laurentiis, M, Bisagni, G, Arpino, G, Sarobba, M, Riccardi, F, Russo, A, Del Mastro, L, Cogoni, A, Cognetti, F, Gori, S, Foglietta, J, Frassoldati, A, Amoroso, D, Laudadio, L, Moscetti, L, Montemurro, F, Verusio, C, Bernardo, A, Lorusso, V, Gravina, A, Moretti, G, Lauria, R, Lai, A, Mocerino, C, Rizzo, S, Nuzzo, F, Carlini, P, Perrone, F, Accurso, A, Agostara, B, Aieta, M, Alabiso, O, Alicicco, M, Amadori, D, Amaducci, L, Amiconi, G, Antuzzi, G, Ardine, M, Ardizzoia, A, Aversa, C, Badalamenti, G, Barni, S, Basurto, C, Berardi, R, Bergamasco, C, Bidoli, P, Bighin, C, Biondi, E, Boni, C, Borgonovo, K, Botta, M, Bravi, S, Bruzzi, P, Buono, G, Butera, A, Caldara, A, Candeloro, G, Cappelletti, C, Cardalesi, C, Carfora, E, Cariello, A, Carrozza, F, Carteni, G, Caruso, M, Casadei, V, Casanova, C, Castori, L, Cavanna, L, Cavazzini, G, Cazzaniga, M, Chilelli, M, Chiodini, P, Chiorrini, S, Ciardiello, F, Ciccarese, M, Cinieri, S, Clerico, M, Coccaro, M, Comande, M, Corbo, C, Cortino, G, Cusenza, S, Daniele, G, D'Arco, A, D'Auria, G, Dazzi, C, De Angelis, C, de Braud, F, De Feo, G, De Matteis, A, De Tursi, M, Di Blasio, A, di Lucca, G, Di Lullo, L, Di Rella, F, Di Renzo, G, Di Stefano, P, Di Stefano, A, Diana, A, Donati, S, Fabbri, A, Fabi, A, Faedi, M, Farina, G, Farris, A, Febbraro, A, Fedele, P, Federico, P, Ferrau, F, Ferretti, G, Ferro, A, Floriani, I, Forcignano, R, Forciniti, S, Forestieri, V, Fornari, G, Frisinghelli, M, Fusco, V, Gallizzi, G, Galvano, A, Gambardella, A, Gambi, A, Gebbia, V, Gervasi, E, Ghilardi, M, Giacobino, A, Giardina, G, Giotta, F, Giraudi, S, Giuliano, M, Grassadonia, A, Grasso, D, Grosso, F, Guizzaro, L, Incoronato, P, Incorvaia, L, Iodice, G, La Verde, N, Labonia, V, Landi, G, Latorre, A, Leonardi, V, Levaggi, A, Limite, G, Lina Bascialla, L, Livi, L, Maiello, E, Mandelli, D, Marcon, I, Menon, D, Montedoro, M, Moraca, L, Moretti, A, Morritti, M, Morselli, P, Mura, A, Mura, S, Musacchio, M, Muzio, A, Natale, D, Natoli, C, Nigro, C, Nistico, C, Nuzzo, A, Orditura, M, Orlando, L, Pacilio, C, Palumbo, G, Palumbo, R, Pasini, F, Paterno, E, Pazzola, A, Pelliccioni, S, Pensabene, M, Perroni, D, Pesenti Gritti, A, Petrelli, F, Piccirillo, M, Pinotti, G, Pogliani, C, Poli, D, Prader, S, Recchia, F, Rizzi, D, Romano, C, Rossello, R, Rossini, C, Salvucci, G, Sanna, V, Santini, A, Saracchini, S, Savastano, C, Scambia, G, Schettini, F, Schiavone, P, Schirone, A, Seles, E, Signoriello, S, Signoriello, G, Silva, R, Silvestri, A, Simeon, V, Spagnoletti, I, Tamberi, S, Teragni, C, Thalmann, V, Thomas, R, Thomas, G, Tienghi, A, Tinari, N, Tinessa, V, Tomei, F, Tonini, G, Torri, V, Traficante, D, Tudini, M, Turazza, M, Vignoli, R, Vitale, M, Zacchia, A, Zagarese, P, Zanni, A, Zavallone, L, Zavettieri, M, Zoboli, A, De Placido S., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M. G., Riccardi F., Russo A., Del Mastro L., Cogoni A. A., Cognetti F., Gori S., Foglietta J., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Verusio C., Bernardo A., Lorusso V., Gravina A., Moretti G., Lauria R., Lai A., Mocerino C., Rizzo S., Nuzzo F., Carlini P., Perrone F., Accurso A., Agostara B., Aieta M., Alabiso O., Alicicco M. G., Amadori D., Amaducci L., Amiconi G., Antuzzi G., Ardine M., Ardizzoia A., Aversa C., Badalamenti G., Barni S., Basurto C., Berardi R., Bergamasco C., Bidoli P., Bighin C., Biondi E., Boni C., Borgonovo K., Botta M., Bravi S., Bruzzi P., Buono G., Butera A., Caldara A., Candeloro G., Cappelletti C., Cardalesi C., Carfora E., Cariello A., Carrozza F., Carteni G., Caruso M., Casadei V., Casanova C., Castori L., Cavanna L., Cavazzini G., Cazzaniga M., Chilelli M., Chiodini P., Chiorrini S., Ciardiello F., Ciccarese M., Cinieri S., Clerico M., Coccaro M., Comande M., Corbo C., Cortino G., Cusenza S., Daniele G., D'arco A. M., D'auria G., Dazzi C., De Angelis C., de Braud F., De Feo G., De Matteis A., De Tursi M., Di Blasio A., di Lucca G., Di Lullo L., Di Rella F., Di Renzo G., Di Stefano P., Di Stefano A., Diana A., Donati S., Fabbri A., Fabi A., Faedi M., Farina G., Farris A., Febbraro A., Fedele P., Federico P., Ferrau F., Ferretti G., Ferro A., Floriani I., Forcignano R., Forciniti S., Forestieri V., Fornari G., Frisinghelli M., Fusco V., Gallizzi G., Galvano A., Gambardella A., Gambi A., Gebbia V., Gervasi E., Ghilardi M., Giacobino A., Giardina G., Giotta F., Giraudi S., Giuliano M., Grassadonia A., Grasso D., Grosso F., Guizzaro L., Incoronato P., Incorvaia L., Iodice G., La Verde N., Labonia V., Landi G., Latorre A., Leonardi V., Levaggi A., Limite G., Lina Bascialla L., Livi L., Maiello E., Mandelli D., Marcon I., Menon D., Montedoro M., Moraca L., Moretti A., Morritti M. G., Morselli P., Mura A., Mura S., Musacchio M., Muzio A., Natale D., Natoli C., Nigro C., Nistico C., Nuzzo A., Orditura M., Orlando L., Pacilio C., Palumbo G., Palumbo R., Pasini F., Paterno E., Pazzola A., Pelliccioni S., Pensabene M., Perroni D., Pesenti Gritti A., Petrelli F., Piccirillo M. C., Pinotti G., Pogliani C., Poli D., Prader S., Recchia F., Rizzi D., Romano C., Rossello R., Rossini C., Salvucci G., Sanna V., Santini A., Saracchini S., Savastano C., Scambia G., Schettini F., Schiavone P., Schirone A., Seles E., Signoriello S., Signoriello G., Silva R. R., Silvestri A., Simeon V., Spagnoletti I., Tamberi S., Teragni C., Thalmann V., Thomas R., Thomas G., Tienghi A., Tinari N., Tinessa V., Tomei F., Tonini G., Torri V., Traficante D., Tudini M., Turazza M., Vignoli R., Vitale M. G., Zacchia A., Zagarese P., Zanni A., Zavallone L., Zavettieri M., Zoboli A., De Placido, S, Gallo, C, De Laurentiis, M, Bisagni, G, Arpino, G, Sarobba, M, Riccardi, F, Russo, A, Del Mastro, L, Cogoni, A, Cognetti, F, Gori, S, Foglietta, J, Frassoldati, A, Amoroso, D, Laudadio, L, Moscetti, L, Montemurro, F, Verusio, C, Bernardo, A, Lorusso, V, Gravina, A, Moretti, G, Lauria, R, Lai, A, Mocerino, C, Rizzo, S, Nuzzo, F, Carlini, P, Perrone, F, Accurso, A, Agostara, B, Aieta, M, Alabiso, O, Alicicco, M, Amadori, D, Amaducci, L, Amiconi, G, Antuzzi, G, Ardine, M, Ardizzoia, A, Aversa, C, Badalamenti, G, Barni, S, Basurto, C, Berardi, R, Bergamasco, C, Bidoli, P, Bighin, C, Biondi, E, Boni, C, Borgonovo, K, Botta, M, Bravi, S, Bruzzi, P, Buono, G, Butera, A, Caldara, A, Candeloro, G, Cappelletti, C, Cardalesi, C, Carfora, E, Cariello, A, Carrozza, F, Carteni, G, Caruso, M, Casadei, V, Casanova, C, Castori, L, Cavanna, L, Cavazzini, G, Cazzaniga, M, Chilelli, M, Chiodini, P, Chiorrini, S, Ciardiello, F, Ciccarese, M, Cinieri, S, Clerico, M, Coccaro, M, Comande, M, Corbo, C, Cortino, G, Cusenza, S, Daniele, G, D'Arco, A, D'Auria, G, Dazzi, C, De Angelis, C, de Braud, F, De Feo, G, De Matteis, A, De Tursi, M, Di Blasio, A, di Lucca, G, Di Lullo, L, Di Rella, F, Di Renzo, G, Di Stefano, P, Di Stefano, A, Diana, A, Donati, S, Fabbri, A, Fabi, A, Faedi, M, Farina, G, Farris, A, Febbraro, A, Fedele, P, Federico, P, Ferrau, F, Ferretti, G, Ferro, A, Floriani, I, Forcignano, R, Forciniti, S, Forestieri, V, Fornari, G, Frisinghelli, M, Fusco, V, Gallizzi, G, Galvano, A, Gambardella, A, Gambi, A, Gebbia, V, Gervasi, E, Ghilardi, M, Giacobino, A, Giardina, G, Giotta, F, Giraudi, S, Giuliano, M, Grassadonia, A, Grasso, D, Grosso, F, Guizzaro, L, Incoronato, P, Incorvaia, L, Iodice, G, La Verde, N, Labonia, V, Landi, G, Latorre, A, Leonardi, V, Levaggi, A, Limite, G, Lina Bascialla, L, Livi, L, Maiello, E, Mandelli, D, Marcon, I, Menon, D, Montedoro, M, Moraca, L, Moretti, A, Morritti, M, Morselli, P, Mura, A, Mura, S, Musacchio, M, Muzio, A, Natale, D, Natoli, C, Nigro, C, Nistico, C, Nuzzo, A, Orditura, M, Orlando, L, Pacilio, C, Palumbo, G, Palumbo, R, Pasini, F, Paterno, E, Pazzola, A, Pelliccioni, S, Pensabene, M, Perroni, D, Pesenti Gritti, A, Petrelli, F, Piccirillo, M, Pinotti, G, Pogliani, C, Poli, D, Prader, S, Recchia, F, Rizzi, D, Romano, C, Rossello, R, Rossini, C, Salvucci, G, Sanna, V, Santini, A, Saracchini, S, Savastano, C, Scambia, G, Schettini, F, Schiavone, P, Schirone, A, Seles, E, Signoriello, S, Signoriello, G, Silva, R, Silvestri, A, Simeon, V, Spagnoletti, I, Tamberi, S, Teragni, C, Thalmann, V, Thomas, R, Thomas, G, Tienghi, A, Tinari, N, Tinessa, V, Tomei, F, Tonini, G, Torri, V, Traficante, D, Tudini, M, Turazza, M, Vignoli, R, Vitale, M, Zacchia, A, Zagarese, P, Zanni, A, Zavallone, L, Zavettieri, M, Zoboli, A, De Placido S., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M. G., Riccardi F., Russo A., Del Mastro L., Cogoni A. A., Cognetti F., Gori S., Foglietta J., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Verusio C., Bernardo A., Lorusso V., Gravina A., Moretti G., Lauria R., Lai A., Mocerino C., Rizzo S., Nuzzo F., Carlini P., Perrone F., Accurso A., Agostara B., Aieta M., Alabiso O., Alicicco M. G., Amadori D., Amaducci L., Amiconi G., Antuzzi G., Ardine M., Ardizzoia A., Aversa C., Badalamenti G., Barni S., Basurto C., Berardi R., Bergamasco C., Bidoli P., Bighin C., Biondi E., Boni C., Borgonovo K., Botta M., Bravi S., Bruzzi P., Buono G., Butera A., Caldara A., Candeloro G., Cappelletti C., Cardalesi C., Carfora E., Cariello A., Carrozza F., Carteni G., Caruso M., Casadei V., Casanova C., Castori L., Cavanna L., Cavazzini G., Cazzaniga M., Chilelli M., Chiodini P., Chiorrini S., Ciardiello F., Ciccarese M., Cinieri S., Clerico M., Coccaro M., Comande M., Corbo C., Cortino G., Cusenza S., Daniele G., D'arco A. M., D'auria G., Dazzi C., De Angelis C., de Braud F., De Feo G., De Matteis A., De Tursi M., Di Blasio A., di Lucca G., Di Lullo L., Di Rella F., Di Renzo G., Di Stefano P., Di Stefano A., Diana A., Donati S., Fabbri A., Fabi A., Faedi M., Farina G., Farris A., Febbraro A., Fedele P., Federico P., Ferrau F., Ferretti G., Ferro A., Floriani I., Forcignano R., Forciniti S., Forestieri V., Fornari G., Frisinghelli M., Fusco V., Gallizzi G., Galvano A., Gambardella A., Gambi A., Gebbia V., Gervasi E., Ghilardi M., Giacobino A., Giardina G., Giotta F., Giraudi S., Giuliano M., Grassadonia A., Grasso D., Grosso F., Guizzaro L., Incoronato P., Incorvaia L., Iodice G., La Verde N., Labonia V., Landi G., Latorre A., Leonardi V., Levaggi A., Limite G., Lina Bascialla L., Livi L., Maiello E., Mandelli D., Marcon I., Menon D., Montedoro M., Moraca L., Moretti A., Morritti M. G., Morselli P., Mura A., Mura S., Musacchio M., Muzio A., Natale D., Natoli C., Nigro C., Nistico C., Nuzzo A., Orditura M., Orlando L., Pacilio C., Palumbo G., Palumbo R., Pasini F., Paterno E., Pazzola A., Pelliccioni S., Pensabene M., Perroni D., Pesenti Gritti A., Petrelli F., Piccirillo M. C., Pinotti G., Pogliani C., Poli D., Prader S., Recchia F., Rizzi D., Romano C., Rossello R., Rossini C., Salvucci G., Sanna V., Santini A., Saracchini S., Savastano C., Scambia G., Schettini F., Schiavone P., Schirone A., Seles E., Signoriello S., Signoriello G., Silva R. R., Silvestri A., Simeon V., Spagnoletti I., Tamberi S., Teragni C., Thalmann V., Thomas R., Thomas G., Tienghi A., Tinari N., Tinessa V., Tomei F., Tonini G., Torri V., Traficante D., Tudini M., Turazza M., Vignoli R., Vitale M. G., Zacchia A., Zagarese P., Zanni A., Zavallone L., Zavettieri M., and Zoboli A.

Abstract

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is regist

Published
2018

91. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

Author

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, and Generali D

Abstract

Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors + endocrine therapy (ET) prolonged progression-free survival as first- or second-line therapy for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer prognosis. Given the recent publication of overall survival (OS) data for the 3 CDK4/6-inhibitors, we performed a meta-analysis to identify a more precise and reliable benefit from such treatments in specific clinical subgroups. Methods: We conducted a systematic literature search to select all available phase II or III randomized clinical trials of CDK4/6-inhibitors + ET reporting OS data in first- or second-line therapy of HR+/HER2-negative pre- or postmenopausal metastatic breast cancer. A random effect model was applied for the analyses. Heterogeneity was assessed with I-2 statistic. Subgroup analysis was performed to explore the effect of study-level factors. The project was registered in the Open Science Framework database (doi: 10.17605/OSF.IO/TNZQP). Results: Six studies were included in our analyses (3421 patients). A clear OS benefit was observed in patients without (hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.54 to 0.85, I-2 = 0.0%) and with visceral involvement (HR = 0.76, 95% CI = 0.65 to 0.89, I-2 = 0.0%), with at least 3 metastatic sites (HR = 0.75, 95% CI = 0.60 to 0.94, I-2 = 11.6%), in an endocrine-resistant (HR = 0.79, 95% CI = 0.67 to 0.93, I-2 = 0.0%) and sensitive subset (HR = 0.73, 95% CI = 0.61 to 0.88, I-2 = 0.0%), for younger than 65 years (HR = 0.80, 95% CI = 0.67 to 0.95, I-2 = 0.0%) and 65 years or older (HR = 0.71, 95% CI = 0.53 to 0.95, I-2 = 44.4%), in postmenopausal (HR = 0.76, 95% CI = 0.67 to 0.86, I-2 = 0.0%) and pre- or perimenopausal setting (HR = 0.76, 95% CI = 0.60 to 0.96, I-2 = 0.0%) as well as in chemotherapy-naive patients (HR = 0.72, 95% CI = 0.55 to 0.93, I-2 = 0.0%). Conclusions: CDK4/6-inhibitors ET combinations compared with ET alone improve OS independent of age, menopausal status, endocrine sensitiveness, and visceral involvement and should be preferred as upfront therapy instead of endocrine monotherapy.

Published
2020

93. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Author

Coombes, R.C., Kilburn, L.S., Snowdon, C.F, Paridaens, R., Coleman, R.E., Jones, S.E., Jassem, J., Van de Velde, C.J.H., Delozier, T., Alvarez, I., Del Mastro, L., Ortmann, O., Diedrich, K., Coates, A.S., Bajetta, E., Holmberg, S.B., Dodwell, D., Mickiewicz, E., Andersen, J., Cocconi, G., Forbes, J., Castiglione, M., Stuart, N., Stewart, A., Fallowfield, L.J., Bertelli, G., Hall, E., Bogle, R.G., Carpentieri, M., Colajori, E., Subar, M., Ireland, E., Bliss, J.M., and Lanning, P.E.

Subjects
Breast cancer -- Drug therapy, Tamoxifen -- Research, Tamoxifen -- Health aspects
Published
2007

96. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study

Author

Vernieri, C., primary, Nichetti, F., additional, Guarneri, V., additional, Cortesi, E., additional, Moscetti, L., additional, Del Mastro, L., additional, Fabbri, A., additional, Curigliano, G., additional, Montemurro, F., additional, Losurdo, A., additional, Generali, D.G., additional, Fabi, A., additional, Pedersini, R., additional, Ciccarese, M., additional, Rocca, A., additional, Arpino, G., additional, La Verde, N.M., additional, Puglisi, F., additional, Mariani, L., additional, and de Braud, F., additional

Published
2020
Full Text
View/download PDF

97. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial

Author

Bianchini, G., primary, Huang, C-S., additional, Egle, D., additional, Bermejo, B., additional, Zamagni, C., additional, Thill, M., additional, Anton, A., additional, Zambelli, S., additional, Russo, S., additional, Ciruelos, E.M., additional, Greil, R., additional, Semiglazov, V., additional, Colleoni, M.A., additional, Kelly, C.M., additional, Mariani, G., additional, Del Mastro, L., additional, Smart, C., additional, Valagussa, P., additional, Viale, G., additional, and Gianni, L., additional

Published
2020
Full Text
View/download PDF

98. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

Author

Molinelli, C., primary, Del Mastro, L., additional, Giraudi, S., additional, Ballestrero, A., additional, Carli, F., additional, Poggio, F., additional, D'Alonzo, A., additional, Dellepiane, C., additional, Buzzatti, G., additional, Blondeaux, E., additional, Conte, B., additional, Pastorino, S., additional, Gallo, M., additional, Lambertini, M., additional, and Bighin, C., additional

Published
2020
Full Text
View/download PDF

99. 187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer

Author

Licata, L., primary, Viale, G., additional, Criscitiello, C., additional, Giordano, A., additional, Chavez-MacGregor, M., additional, Curigliano, G., additional, Foldi, J., additional, Oke, O., additional, Giuliano, M., additional, Collins, R.J., additional, Del Mastro, L., additional, Puglisi, F., additional, Montemurro, F., additional, Vernieri, C., additional, Gerratana, L., additional, Barnato Giordano, S., additional, Rognone, A., additional, Sica, L., additional, Pusztai, L., additional, and Bianchini, G., additional

Published
2020
Full Text
View/download PDF

100. 1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities

Author

Poggio, F., primary, Tagliamento, M., additional, Di Maio, M., additional, Martelli, V., additional, De Maria, A., additional, Barisione, E., additional, Grosso, M., additional, Boccardo, F., additional, Pronzato, P., additional, Del Mastro, L., additional, and Lambertini, M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results